- Home
- DBD vs RARE Comparison
DBD vs RARE Comparison
Compare DBD & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBD
- RARE
- Stock Information
- Founded
- DBD 1859
- RARE 2010
- Country
- DBD United States
- RARE United States
- Employees
- DBD N/A
- RARE N/A
- Industry
- DBD EDP Services
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- DBD Technology
- RARE Health Care
- Exchange
- DBD Nasdaq
- RARE Nasdaq
- Market Cap
- DBD 2.2B
- RARE 2.6B
- IPO Year
- DBD N/A
- RARE 2014
- Fundamental
- Price
- DBD $61.28
- RARE $29.81
- Analyst Decision
- DBD Strong Buy
- RARE Strong Buy
- Analyst Count
- DBD 2
- RARE 14
- Target Price
- DBD $75.00
- RARE $86.64
- AVG Volume (30 Days)
- DBD 215.1K
- RARE 1.5M
- Earning Date
- DBD 08-06-2025
- RARE 08-05-2025
- Dividend Yield
- DBD N/A
- RARE N/A
- EPS Growth
- DBD N/A
- RARE N/A
- EPS
- DBD N/A
- RARE N/A
- Revenue
- DBD $3,672,300,000.00
- RARE $610,159,000.00
- Revenue This Year
- DBD $3.09
- RARE $19.72
- Revenue Next Year
- DBD $2.74
- RARE $23.29
- P/E Ratio
- DBD N/A
- RARE N/A
- Revenue Growth
- DBD N/A
- RARE 26.77
- 52 Week Low
- DBD $34.88
- RARE $25.81
- 52 Week High
- DBD $63.46
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- DBD 62.36
- RARE 54.94
- Support Level
- DBD $62.12
- RARE $29.04
- Resistance Level
- DBD $63.46
- RARE $30.52
- Average True Range (ATR)
- DBD 1.21
- RARE 0.74
- MACD
- DBD 0.05
- RARE 0.34
- Stochastic Oscillator
- DBD 73.83
- RARE 89.20
About DBD Diebold Nixdorf Incorporated Common stock
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.